Immunolocalization and mRNA expression of bone morphogenetic protein-6 in human clear cell renal carcinoma

Kidney and Blood Pressure Research

Volumn 32, Issue 6, 2010, Pages 445-450

  Basic Jukic, Nikolina ^a   Radic Antolic, Margareta ^a   Hudolin, Tvrtko ^a   Coric, Marijana ^a   Zadro, Renata ^a   Pasini, Josip ^a   Kastelan, Zeljko ^a   Kes, Petar ^a  

^a KBC Zagreb   (Croatia)

Author keywords

Bone morphogenetic protein 6; Clear cell renal carcinoma; Expression

Indexed keywords

ANTIBODY; BONE MORPHOGENETIC PROTEIN 6; MESSENGER RNA;

ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CLEAR CELL CARCINOMA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPLASM; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOLOCALIZATION; KIDNEY CARCINOMA; KIDNEY PARENCHYMA; MALE; NEPHRECTOMY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION;

ADENOCARCINOMA, CLEAR CELL; ADULT; AGED; AGED, 80 AND OVER; BONE MORPHOGENETIC PROTEIN 6; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEPHRECTOMY; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 72049112863     PISSN: 14204096     EISSN: None     Source Type: Journal    
DOI: 10.1159/000266479     Document Type: Article

References (33)

1. Athar U, Gentile TC: Treatment options for metastatic renal cell carcinoma: a review. Can J Urol 2008; 15:3954-3966.
2. Dalle S, Thieblemont C, Thomas L, Dumontet C: Monoclonal antibodies in clinical oncology. Anticancer Agents Med Chem 2008; 8:523-532.
3. Coppin C: Immunotherapy for renal cell cancer in the era of targeted therapy. Expert Rev Anticancer Ther 2008;8:907-919.
4. Sciarra A, Gentile V, Salciccia S, Alfarone A, Di Silverio F: New anti-angiogenic targeted therapy in advanced renal cell carcinoma (RCC): current status and future prospects. Rev Recent Clin Trials 2008;3:97-103.
5. Simpson D, Curran MP: Temsirolimus: in advanced renal cell carcinoma. Drugs 2008; 68:631-638.
6. Reddi AH: Bone morphogenetic proteins: from basic science to clinical applications. J Bone Joint Surg 2001;83:1-6.
7. Urist MR: Bone: formation by autoinduction. Science 1965;150:893-899.
8. Chen D, Zhao M, Mundy GR: Bone morphogenetic proteins. Growth Factors 2004;22: 233-241.
9. Motoyama K, Tanaka F, Kosaka Y, et al: Clinical significance of BMP-7 in human colorectal cancer. Ann Surg Oncol 2008; 15:1530-1537.
10. Hsu MY, Rovinsky SA, Lai CY, et al: Aggressive melanoma cells escape from BMP-7-mediated autocrine growth inhibition through coordinated Noggin upregulation. Lab Invest 2008;88:842-855.
11. Alarmo EL, Rauta J, Kauraniemi P, Karhu R, Kuukasjarvi T, Kallioniemi A: Bone morphogenetic protein 7 is widely overexpressed in primary breast cancer. Genes Chromosomes Cancer 2006;45:411-419.
12. Haudenschild DR, Palmer SM, Moseley TA, You Z, Reddi H: Bone morphogenetic protein (BMP)-6 signaling and BMP antagonist noggin in prostate cancer. Cancer Res 2004; 64:8276-8284.
13. Yanagita M: BMP antagonists: their roles in development and involvement in patophysiology. Cytokine Growth Factor Rev 2005; 16: 309-317.
14. Deng H, Makizumi R, Ravikumar TS, Dong H, Yang W, Yang WL: Bone morphogenetic protein-4 is overexpressed in colonic adenocarcinomas and promotes migration and invasion of HCT116 cells. Exp Cell Res 2007; 313:1033-1044.
15. Kwak C, Park YH, Kim IY, Moon KC, Ku JH: Expression of bone morphogenetic proteins, the subfamily of the transforming growth factor-beta superfamily, in renal cell carcinoma. J Urol 2007; 178:1062-1067.
16. Bentley H, Hamdy FC, Hart KA, et al: Expression of bone morphogenetic proteins in human prostatic adenocarcinoma and benign prostatic hyperplasia. Br J Cancer 1992; 66:1159-1163.
17. Hamdy FC, Autzen P, Robinson MC, Home CH, Neal DE, Robson CN: Immunolocalization and messenger RNA expression of bone morphogenetic protein-6 in human benign and malignant prostates tissue. Cancer Res 1997;57:4427-4431.
18. Autzen P, Robson CN, Bjartell A, et al: Bone morphogenetic protein 6 in skeletal metastases from prostate cancer and other common human malignancies. Br I Cancer 1998;78: 1219-1223.
19. De Pinieux G, Flam T, Zerbib M, et al: Bone sialoprotein, bone morphogenetic protein 6 and thymidine phosphorylase expression in localized human prostatic adenocarcinoma as predictors of clinical outcome: a clinico-pathological and immunohistochemical study of 43 cases. I Urol 2001; 166:1924-1930.
20. Thomas BG, Hamdy FC: Bone morphogenetic protein-6: potential mediator of osteoblastic metastases in prostate cancer. Prostate Cancer Prostatic Dis 2000;3:283-285.
21. Darby S, Cross SS, Brown NJ, Hamdy FC, Robson CN: BMP-6 over-expression in prostate cancer is associated with increased Id-1 protein and a more invasive phenotype. I Pathol 2008;214:394-404.
22. Yang S, Du J, Wang Z, et al: BMP-6 promotes E-cadherin expression through repressing delta EF1 in breast cancer cells. BMC Cancer 2007;7:211.
23. Sivertsen EA, Huse K, Hystad ME, Kersten C, Smeland EB, Myklebust JH: Inhibitory effects and target genes of bone morphogenetic protein 6 in Jurkat Tag cells. Eur I Immunol 2007;37:2937-2948.
24. Daibaty M, Nemoto Y, Bandobashi K, et al: promoter hypermethylation of the bone morphogenetic protein-6 gene in malignant lymphoma. Clin Cancer Res 2007;13:3528-3535.
25. Kraunz KS, Nelson HH, Liu M, Wiencke JK, Kelsey KT: Interaction between the bone morphogenetic proteins and Ras/MAP-kinase signalling pathways in lung cancer. Br I Cancer 2005;93:949-952.
26. Chen AL, Fang C, Liu C, Leslie MP, Chang E, Di Cesare PE: Expression of bone morphogenetic proteins, receptors, and tissue inhibitors in human fetal, adult, and osteoarthritic articular cartilage. J Orthop Res 2004;22: 1188-1192.
27. Ogawa K, Utsunomiya T, Minori K et al. Clinical significance of elongation factor-1 delta mRNA expression in oesophageal carcinoma. Br I Cancer 2004;91:282-286.
28. Robson CJ, Churchill BM, Anderson W: The results of radical nephrectomy for renal cell carcinoma. J Urol 1969;101:297-301.
29. Fuhrman SA, Lasky LC, Limas C: Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982; 6:655-663.
30. Sulzbacher I, Birner P, Trieb K, Pichlbauer E, Lang S: The expression of bone morphogenetic proteins in osteosarcoma and its relevance as a prognostic parameter. I Clin Pathol 2002;55:381-385.
31. Langenfeld EM, Bojnowski J, Perone J, Langenfeld J: Expression of bone morphogenetic proteins in human lung carcinomas. Ann Thorac Surg 2005;80:1028-1032.
32. Akiyoshi T, Uchida K, Tateyama S: Expression of bone morphogenetic protein-6 and bone morphogenetic protein receptors in myoepithelial cells of canine mammary gland tumors. Vet Pathol 2004;41:154-673.
33. Kim IY, Lee DH, Lee DK, et al: Decreased expression of bone morphogenetic protein (BMP) receptor type II correlates with insensitivity to BMP-6 in human renal cell carcinoma cells. Clin Cancer Res 2003;9:6046-6051.